David J. Schlanger - 08 May 2023 Form 4 Insider Report for Progyny, Inc. (PGNY)

Role
Executive Chairman, Director
Signature
/s/ Mark Livingston, Attorney-in-Fact
Issuer symbol
PGNY
Transactions as of
08 May 2023
Net transactions value
-$5,998,870
Form type
4
Filing time
10 May 2023, 16:24:45 UTC
Previous filing
25 Apr 2023
Next filing
12 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PGNY Common Stock Options Exercise $61,777 +67,887 +92% $0.9100* 141,374 08 May 2023 Direct
transaction PGNY Common Stock Sale $2,383,513 -67,887 -48% $35.11 73,487 08 May 2023 Direct F1, F2
transaction PGNY Common Stock Options Exercise $91,000 +100,000 +136% $0.9100* 173,487 09 May 2023 Direct
transaction PGNY Common Stock Sale $258,871 -7,025 -4% $36.85 166,462 09 May 2023 Direct F1, F3
transaction PGNY Common Stock Sale $2,763,771 -73,485 -44% $37.61 92,977 09 May 2023 Direct F1, F4
transaction PGNY Common Stock Sale $745,492 -19,490 -21% $38.25 73,487 09 May 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PGNY Stock Option (Right to Buy) Options Exercise $0 -67,887 -9.9% $0.000000 616,821 08 May 2023 Common Stock 67,887 $0.9100 Direct F6
transaction PGNY Stock Option (Right to Buy) Options Exercise $0 -100,000 -16% $0.000000 516,821 09 May 2023 Common Stock 100,000 $0.9100 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 6, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.05 to $37.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.05 to $38.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $38.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 These options are fully vested and exercisable.